ALK announced that Carsten Hellman will step down as President & CEO at the end of 2023. He will be succeed by Peter Halling no later than 1 January 2024. The Board of Directors and Carsten Hellmann have reached a mutual agreement, that Carsten will step down as President & CEO of ALK at the end of 2023 to pursue a non-executive career after leading the successful development and positioning of ALK on the global allergy market for almost seven years.

Carsten Hellmann will continue to manage his responsibilities until Peter Halling takes over. Peter Halling will assume the position as President & CEO of ALK no later than 1 January 2024. Peter Halling (45) is currently CEO of Fertin Pharma, a leading specialist contract development and manufacturing organisation in innovative oral and intra-oral delivery technologies including pharmaceutical products, which he, together with private-equity firm EQT, led through a successful sale in 2021.

Before joining Fertin Pharma in 2020, he held several international executive roles at Novozymes A/S, Ingredion Inc. and Doehler Group GmbH, successfully managing diverse businesses in countries such as the USA and Germany. Peter holds an M.Sc. from Copenhagen Business School.